Liu Jessica Y, Lowe Michael
Department of Surgery, Emory University, Atlanta, Georgia.
Division of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, Georgia.
J Surg Oncol. 2019 Jan;119(2):216-221. doi: 10.1002/jso.25352. Epub 2018 Dec 27.
Neoadjuvant therapy has demonstrated promise as a treatment modality in resectable advanced-stage melanoma. Treatment has evolved beyond chemotherapy, with the utilization of biochemotherapy, immunotherapy, and targeted therapy in the neoadjuvant setting. These therapies have shown better progression-free survival and melanoma-specific survival when compared with patients that proceed directly to surgery. Ongoing clinical trials will continue to propel research forward to improve the available options for patients with resectable advanced regional disease.
新辅助治疗已被证明有望成为可切除晚期黑色素瘤的一种治疗方式。治疗方法已从化疗发展而来,在新辅助治疗中采用了生物化疗、免疫治疗和靶向治疗。与直接进行手术的患者相比,这些治疗方法显示出更好的无进展生存期和黑色素瘤特异性生存期。正在进行的临床试验将继续推动研究向前发展,以改善可切除晚期区域疾病患者的现有治疗选择。